Blue rose reveals true RNAi colours

By Renate Krelle
Wednesday, 30 March, 2005

The CSIRO has revealed that part of the technology used to develop the blue rose -- unveiled last year by Japanese giant Suntory and its subsidiary, Melbourne company Florigene -- was an RNAi technique developed by CSIRO for gene replacement in plants.

In its first commercial application in plants, the CSIRO-developed RNAi technology was used to inactivate the gene encoding the enzyme dihydroflavonol reductase (DFR) in roses. The enzyme directs the synthesis of red pigments in the flower.

An RNAi molecule which hybridises with the rose DFR gene was used to inhibit the gene's expression. Scientists then inserted Florigene's patented iris DFR gene -- which makes a lot of blue pigment - plus the delphinidin gene from pansy, a gene missing in roses, to produce a blue rose.

The blue rose has yet to gain regulatory approval before it can be commercially grown and marketed.

Related News

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd